Onapristone ER + Onapristone ER + Anastrozole
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Granulosa Cell Ovarian Cancer
Conditions
Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer, Endometrioid Endometrial Cancer
Trial Timeline
May 2, 2019 → Sep 3, 2024
NCT ID
NCT03909152About Onapristone ER + Onapristone ER + Anastrozole
Onapristone ER + Onapristone ER + Anastrozole is a phase 2 stage product being developed by Context Therapeutics for Granulosa Cell Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03909152. Target conditions include Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer, Endometrioid Endometrial Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03909152 | Phase 2 | Completed |